Sonia P.

Supported a consumer wellbeing app pivoting towards a B2B model, with limited clarity on organisational value and no established sales infrastructure. The challenge was to identify a credible organisational use case and a realistic route to market.

Identified neurodivergent support as the strongest organisational entry point and built an evidence-led positioning aligned with employer needs. Defined a viable B2B entry route via workplace benefits platforms and supporting commercial narrative.

The work led to early commercial traction, first deals entering the pipeline within weeks, and reduced risk of pursuing ineffective go-to-market strategies.

Worked with a digital health company preparing to enter the US B2B market, initially seeking tactical content support but lacking a clear strategic buyer framework. The leadership team needed clarity on who would buy, why, and how to communicate value credibly in a new market.

Delivered a structured strategy combining buyer priorities, public health burden data, and real user language to define priority segments and a coherent value narrative. Translated insight into clear strategic direction and commercial assets.

Resulted in a board-ready market entry strategy, sharper buyer focus, and avoidance of significant wasted spend on low-impact go-to-market activity.

Supported a clinically led mental wellbeing company operating in a competitive employer market where buyers increasingly required proof of impact. The team had strong clinical credibility but lacked a clear commercial evidence narrative to support sales, renewals, and bids.

Led the development of an evidence and outcomes strategy aligned to buyer decision-making, translating clinical insight into a defensible employer-facing value story. Equipped the commercial team with clear proof points to handle buyer scrutiny with confidence.

The work underpinned successful bids and renewals, contributing to revenue growth from £0 to £3.2m ARR.

Currently leading a feasibility and market-entry assessment for a US-based biotech company evaluating expansion into the UK. The work is designed to inform a board-level decision on whether the UK represents a viable and strategically sound next market.

The engagement includes analysis of market demand, buyer landscape, regulatory and system-level considerations, and commercial risk factors. Outputs are structured to support executive and board discussion rather than operational execution.

This work will directly inform a forthcoming board decision on UK market entry and investment allocation.